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Introduction 
 The majority of permanent CNS damage resulting from cerebral ischemia is mediated by 
endogenous secondary processes (1, 2).  Although, neuronal cell death evolves over several days 
(3, 4), the trajectory of recovery is likely determined early with acute inflammatory events 
participating in the secondary injury process (5, 6). The delay in damage following cerebral 
ischemia provides a potential therapeutic window for reducing injury. This suggests immediate 
post-recovery environment may play a crucial role in establishing levels of neuroinflammation 
and neuronal damage that occur post-ischemia. Preventing CNS damage following cerebral 
ischemia influences long-term survival as well as cognitive and psychological outcome. 
 One environmental factor that is particularly variable in the hospital setting is nighttime 
light exposure. Hospital intensive care units have inconsistent levels of lighting during both day 
and night (7). These disruptive lighting conditions may influence patient recovery because light 
is the most potent entraining signal for the biological circadian clock (suprachiasmatic nuclei; 
SCN) in mammals; extrinsic light information travels directly from the retina to the SCN via the 
retinohypothalamic tract. Light input to the SCN coordinates internal signals, synchronizing 
daily physiological rhythms to the external light-dark cycle (8). 
 Circadian rhythms are important for homeostatic functions including those associated 
with the immune systems (9). There are circadian components to many immunological processes 
including antigen presentation, toll-like receptor function, cytokine gene expression and 
lymphocyte proliferation (10, 11). Furthermore, many immune cells such as natural killer cells, 
macrophages, dendritic cells, and B cells possess molecular clock mechanisms necessary for 
self-sustaining oscillations (12-14). In healthy individuals, circadian misalignment can be rapidly 
induced with aberrant lighting schedules, resulting in adverse metabolic and cardiovascular 
consequences (15) .  Individuals chronically exposed to LAN are at increased risk for heart 
disease (16), cancer (17, 18), disrupted rhythmicity of neuroendocrine function (such as 
corticotrophin releasing hormone, glucocorticoids, and prolactin) (19, 20), and mood disorders 
(21); a common risk factor in each of these pathologies is elevated inflammation. Moreover, shift 
workers have altered immune parameters including elevated C-reactive protein and increased 
leukocyte count (22).  Importantly, circadian disruption dysregulates inflammatory responses 
independently of sleep loss or stress (23).   
Cardiac arrest has both seasonal (i.e. day length) and circadian (i.e. time of day) patterns 
of  incidence and recovery (24-26), suggesting a role for light in altering the physiological 
response to cerebral ischemia. Light exposure may be particularly salient to CA-induced 
neuroinflammation. Although several mechanisms contribute to damage following ischemic 
injury, including energetic failure, excitotoxicity, and oxidative damage (reviewed in (5, 6), 
manipulation of inflammatory responses are considered a prime target for improving recovery.  
Following CA an inflammatory response is triggered by activation of microglia and astrocyes 
with a corresponding upregulation of pro-inflammatory cytokines (27). IL-1β and (TNFα) are 
pro-inflammatory cytokines which are upregulated within hours following global ischemia (1) 
and exacerbate injury. For example, increased levels of hippocampal TNFα and IL-1β after CA 
are associated with elevated neuronal cell death one week later in a mouse model of CA (25). 
Administration of mesenchymal stromal cells into the hippocampus following global ischemia 
decreases expression of many genes involved in inflammation and immune responses and 
reduces neuronal death (28). Likewise, inhibition of cyclooxygenase-2 (COX2), a mediator of 
inflammatory activity, decreases CA1 neuronal death resulting from cerebral ischemia (29, 30).  
 Dim light at night disrupts the circadian system and immune function implicating it as a 
critical factor for consideration in cardiac arrest outcome. We hypothesized that light at night 
would potentiate injury following cardiac arrest. Here we show the neurobiological effects of 
environmental lighting on CA outcome.  Consistent with our hypotheses, light at night following 
CA enhanced acute cytokine responses, increased neuronal death, and resulted in higher short-
term mortality. Moreover, the effects of light at night were ameliorated through inhibition of 
cytokines and manipulation of the light source. 
Results 
Hospital lighting levels 
 In order to assess typical lighting environments for patients recovering in hospital 
settings, HOBO light loggers (Onset, Bourne, MA) were placed in patient rooms at The Ohio 
State University Wexner Medical Center Hospital. Significant nighttime light intrusions were 
observed in all units monitored, including the intensive care, post-surgical, and cardiac intensive 
care units (Fig. 1a; representative patient lighting). Patients experienced light levels as high as 
100 lux several times each night between the hours of 11PM and 6AM. After confirming 
nighttime light disruptions in patient rooms, we used a mouse model of CA to determine whether 
exposure to dim light at night influences recovery following global cerebral ischemia. 
 Dim light at night increases mortality and hippocampal damage following CA 
 Eight week old Swiss Webster mice were acclimated to a standard light dark cycle [14h 
light (150 lux): 10h dark (0 lux); LD] and then underwent a CA or SHAM procedure (Fig. S1). 
Following the procedure mice either remained in LD cycle or were transferred to a bright light-
dim light cycle [14h light (150 lux): 10h dim light (5 lux); dLAN]. As anticipated, there was 
100% survival in both SHAM groups. In contrast, CA significantly reduced survival compared to 
the SHAM procedure (p < 0.05; Fig 1b) and among the CA mice, mortality in the dLAN group 
was four-fold higher than in the LD group. These data suggest that modest changes in the 
recovery environment affect cardiac arrest survival.  
 The reduced survival rate of mice exposed to dLAN may reflect increased 
neuroinflammation and hippocampal cell death. One week following CA or SHAM procedures 
mice were anesthetized and perfused transcardially with ice cold saline followed by 4% 
paraformaldehyde. Brains were cryoprotected, frozen, sectioned, and processed for Fluoro-
JadeC, a marker for degenerating neurons. The Fluoro-JadeC labeled tissue was used to evaluate 
cell death in the hippocampus, a brain region particularly vulnerable to ischemic damage (31). 
As expected, cell death was uniformly low among SHAM mice (Fig. 1c,d), and significantly 
elevated among mice subjected to CA (Fig. 1 e,f,g). Moreover, mice exposed to dLAN had 
significantly more cell death in the hippocampus one week after CA compared with mice 
exposed to dark nights (Fig. 1c-g). Hippocampal cell death is an excellent proxy for overall 
recovery after global ischemia as increased hippocampal damage is associated with elevated 
mortality and memory deficits, as well as impaired affective responses (32-36).  
Dim light at night alters acute inflammatory status 
 The inflammatory response following global ischemia is an important factor in recovery. 
Thus, we investigated whether dLAN alters the expression of pro-inflammatory cytokines 
following CA.  Brain tissue was collected 24 h after CA or SHAM procedures, i.e. after only a 
single night of post-ischemic dLAN or LD. The brains were rapidly removed and placed in RNA 
later. The following day, hippocampi were dissected out and used for quantitative real time PCR 
(qRT-PCR) analyses of pro-inflammatory cytokines. As expected, TNFα, IL1β, and IL6 gene 
expression were elevated among CA compared to SHAM mice (p < 0.05; Fig 2a-c). Moreover, 
exposure to a single night of dLAN after CA was sufficient to upregulate expression of TNFα 
and IL1β, compared to mice exposed to a dark night (p < 0.05; Fig. 2a,b). The increase in pro-
inflammatory cytokine expression may occur very early after placement back in lighting 
conditions. Indeed, a difference in post-CA TNFα expression was apparent after as little as 4 hr 
of total darkness versus dim light (p < 0.05; Fig. 2d). There were no differences in hippocampal 
cytokine gene expression between dLAN and LD mice that underwent the SHAM procedure (p > 
0.05). In sum, acute upregulation of inflammatory markers among CA mice housed in dLAN 
may contribute to the increased hippocampal neuronal death and mortality observed in this 
group. 
 Microglia are the resident immune cells in CNS and perturbations of the 
microenvironment can induce microglial activation, resulting in altered morphology and 
secretion of pro-inflammatory mediators (37, 38). Therefore, we hypothesized that microglia 
increase cytokine expression 24 h after CA in dLAN mice, contributing to the overall elevation 
in inflammatory status in the dLAN-CA group. Microglia were extracted from whole brain tissue 
using a Percoll gradient 24 h after CA or SHAM procedures (a single night of dLAN or LD 
lighting conditions). mRNA was extracted immediately following microglial isolation and pro-
inflammatory cytokine expression was evaluated. IL-1β and TNF-α mRNA expression was 
significantly higher in microglia isolated from CA mice as compared to SHAM mice (p < 0.05; 
Fig. 2e,f). Furthermore, exposure to a single night of dLAN after CA elevated microglial IL-1β 
and IL-6 mRNA relative to LD (p < 0.05; Fig 2f,g). These results suggest that microglia may be 
partially responsible for the proinflammatory bias observed among mice that were housed in 
dLAN after CA.  
 We also examined whether altered circulating glucocorticoid concentrations could  be 
contributing to the impaired recovery after CA because elevated corticosterone has previously 
been associated with increased CA-induced neuroinflammation and neuronal death (39). 
However, altered corticosteroid responses do not appear to underlie the differences in ischemic 
outcome between the CA-LD and CA-dLAN groups; there were no differences in corticosterone 
concentrations between CA or SHAM groups at 24h (p > 0.05; Fig. 2h). Moreover, investigation 
of corticosterone concentration at 6 hr intervals following CA did not reveal any significant 
differences between the CA-dLAN and CA-LD groups during the first 24 h of recovery (p > 
0.05; Fig. S2). 
Inhibition of selective pro-inflammatory cytokines ameliorates light induced damage 
 Although several mechanisms contribute to damage following ischemic injury, including 
energetic failure, excitotoxicity, and oxidative stress (reviewed in (6), manipulation of 
inflammatory responses are considered a prime target for prevention of damage. Following 
ischemic brain damage both selective (against specific cytokines; e.g., IL1 receptor antagonist 
(IL1-ra) administration) and non-selective (e.g. minocycline) inhibition of pro-inflammatory 
cytokines ameliorate damage improving recovery and behavioral outcomes (39-42). Because our 
results indicate that IL-1β, TNF-α, and IL-6 mRNA expression is greater among CA-dLAN mice 
compared to CA-LD mice, we hypothesized that selective inhibition of these pro-inflammatory 
cytokines would improve outcome following CA-dLAN. Three days prior to the CA procedure, 
mice were implanted with a cannula directed at the lateral ventricle. Two hours following CA, 
mice were administered a single 2μL ICV injection of either the vehicle (artificial cerebrospinal 
fluid; aCSF), mouse IL6 neutralizing antibody (IL6-na), TNF monoclonal antibody (infliximab; 
IFX), or recombinant mouse IL-1 receptor antagonist (IL1-ra).  Hippocampal cell death was 
evaluated using Fluoro-JadeC as described above. IL1-ra and IFX decreased hippocampal cell 
death compared to aCSF treatment among CA-dLAN (p < 0.05; Fig. 3b), producing levels of 
neuronal death that were similar to CA-LD mice treated with the vehicle (p>0.05). In contrast, 
treatment with IL6-na did not ameliorate hippocampal neuronal damage associated with CA-
dLAN.  
 A similar pattern was apparent for microglial activation, which is often used as an index 
of neuroinflammation (43). Brain tissue was labeled with Iba-1, an antibody directed against 
microglia; increased Iba-1 surface area suggests microglial activation (44). Significantly greater 
microglial activation in the CA1, CA2, and CA3 subfields of the hippocampus was apparent  
among the CA-dLAN  mice treated with the vehicle (aCSF)  relative to the CA-LD mice treated 
with the vehicle (p < 0.05; Fig. 3c-i). Furthermore, treatment of CA-dLAN mice with IL1-ra or 
IFX reduced microglia activation in the CA1, CA2, and CA3 (p < 0.05; Fig. 3c-i) relative to the 
CA-dLAN mice treated with vehicle. Iba1 expression in CA-dLAN mice treated with IL1-ra or 
IFX did not differ from CA-LD mice treated with the vehicle in any of the hippocampal subfields 
quantified. In contrast, CA-dLAN mice treated with IL-6na had levels of microglial activation in 
the CA1 that were comparable to CA-dLAN mice treated with the vehicle, while levels of 
microglial activation in the CA2 and CA3 regions were intermediate between vehicle treated 
CA-dLAN and CA-LD mice. Thus, inhibiting IL-1 and TNF-α signaling in CA-dLAN mice 
normalized the microglial and neurodegenerative responses. Furthermore, the results suggest IL-
1 and TNF- α cytokine pathways may be more involved than IL6 in inducing hippocampal 
damage. 
Alternative spectra of lighting minimize light induced damage 
 In terms of the circadian system, not all lighting is created equal. The intrinsically 
photosensitive retinal ganglion cells (ipRGCs) that project to the master circadian pacemaker in 
the SCN contain melanopsin and are most responsive to the blue region of the visible light 
spectrum ranging from 450 to 485 nm. These wavelengths are present in broad spectrum white 
light such as natural sunlight and the majority of indoor lighting. Longer wavelengths of lighting 
do not activate ipRGCs and therefore minimally influence the circadian system (45, 46). Thus, 
we hypothesized that mice exposed to red light at night would more closely resemble the LD 
phenotype than the dLAN phenotype. Following CA, mice were placed in LD, dLAN [14 h light 
(150 lux): 10 h dim light (5 lux; 6500K cool white light- containing blue wavelengths)] or a 
bright-dim red light cycle [rLAN; 14 h light (150 lux): 10 h dim red (5 lux; 636 nm)]. Tissue was 
collected seven days later, for analysis of neuronal damage via Fluoro-JadeC and microglial 
activation via Iba-1, as described above.   
 Unlike full spectrum light at night, dim red light at night did not increase mortality 
following CA. There were no differences in mortality between CA mice exposed to rLAN versus 
LD (p > 0.05; Fig. 4a). As in the first experiment, CA-dLAN increased hippocampal cell death 
compared to CA-LD (p < 0.05; Fig. 4b, d-f). In contrast, rLAN did not exacerbate ischemic cell 
death. Hippocampal neuronal damage among CA-rLAN mice resembled that of CA-LD mice (p 
> 0.05) and there was significantly less damage among rLAN mice compared to dLAN mice 
following CA (p < 0.05; Fig. 4b, d-f). We similarly replicated our findings that CA-dLAN 
exhibited increased microglia activation in multiple hippocampal subfields compared to CA-LD 
conspecifics (p < 0.05; Fig. 4c, g-i). In contrast, rLAN did not increase post-ischemic microglia 
activation relative to CA-LD (p > 0.05; Fig. 4c, g-i). These results indicate that standard indoor 
lighting may potentiate neuroinflammation and neuronal damage following CA, whereas 
alternative lighting using wavelengths greater than ~600nm does not produce the same 
detrimental biological responses. 
Discussion 
 Cardiovascular disease is the leading causes of death in the US (47).  The survival rate 
for cardiac arrest is very low, and the majority of patients who survive live with extensive 
physical, cognitive, and affective disabilities (48-50). However, our murine results indicate that 
adjusting environmental lighting could prove to be an inexpensive and effective way to improve 
patient outcome in cardiac intensive care units.  Because of patient safety concerns and the need 
for monitoring, hospital ICU rooms are rarely completely dark and it is not uncommon for 
patients to be exposed to bright lights (100 lux) several times per night (Figure 1; (7)). Indeed, 
even patients whose eyelids are closed may be affected by the light intrusion (51).  Here we 
show that exposing mice to as little as 5 lux of dim light at night after resucitation from CA 
exacerbates neuroinflammation and neuronal damage, and increases short-term mortality four-
fold relative to mice that are maintained in a consistent light-dark cycle. The effects on neuronal 
damage and mortality appear to be mediated by increased neuroinflammation among CA mice 
exposed to dLAN. Indeed, TNF-α mRNA expression in the hippocampus is elevated as early as 4 
h after exposure to dLAN, and by 24 h the CA-dLAN group has significantly greater TNF-α, IL-
1β, and IL-6 mRNA expression compared to the CA-LD group (Fig. 2). These pro-inflammatory 
cytokines are known to contribute to damage after cerebral ischemia (52, 53). Thus, early 
changes in the inflammatory response caused by light at night may alter the trajectory of 
recovery resulting in higher mortality and increased neuronal damage characterized after one 
week. 
 Inhibition of TNF-α, IL-1, or IL-6 signaling among CA-dLAN mice produced 7-day 
survival rates that approximated or exceeded the survival rate for the CA-LD group (Fig. 3a), 
although only treatment with IL-1ra or IFX significantly reduced microglial activation and 
neuronal damage relative to the CA-dLAN mice. Thus, two bodies of evidence point to a role of 
increased inflammatory responses in mediating elevated neuronal damage among the CA-dLAN 
mice: (1) both proinflammatory cytokine gene expression and neuronal damage were elevated 
after exposure to dLAN relative to LD and (2) treatment with IL1ra or IFX prevented the 
exacerbation of neuronal damage and microglial activation observed among vehicle treated CA-
dLAN mice.  
 Although pharmacological intervention clearly abated the detrimental effects of dLAN on 
CA-induced microglial activation, neuronal damage, and short-term mortality, a far simpler 
approach to improving CA outcome is to modify the physical qualities of the nighttime light to 
prevent increased neuroinflammation. For example, night time red light of the same illuminance 
as the dim white light did not exacerbate CA-induced neuronal damage or microglial activation 
in mice. Indeed, the CA-rLAN mice did not differ significantly from CA-LD mice in either of 
these measures (Figure 3). These data are consistent with studies reporting that red light at night 
does not affect other aspects of physiology and behavior in humans or other animals to the same 
extent as broad spectrum white light that contains blue wavelengths (54). The effects of night 
time light are likely mediated by the suprachiasmatic nucleus or “master circadian clock”, which 
receives input from melanopsin containing ipRGCs in the retina. The ipRCGs are activated by 
blue light (~480nm, found in outdoor and most indoor lighting, especially fluorescent lights), but 
are unaffected by long wavelength light, such as red light. The minimal influence of red light 
compared to white light on CA recovery suggests that light recognition by the circadian system 
is involved in dim white light induced exacerbation of CA damage. 
 In sum, the mouse data presented here suggest that exposure to light at night, a common 
occurrence in hospital rooms, increases short-term mortality and compromises recovery from 
cerebral ischemia by exacerbating neuroinflammation. Using red lights at night in hospital rooms 
or having patients wear goggles that filter lower wave length light could be inexpensive solutions 
that allow visibility without priming the immune system of the patients. If the effects of white 
light at night are replicated in cardiovascular patients, these results could have important 
implications for the design of lighting in clinical settings and could apply to a broad number of 
conditions and medical procedures that involve ischemia and inflammation, such as stroke, 
cardiovacular artery bypass graft, sickle cell disease, sleep apnea, and organ transplant.  
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Figure 1. Dim light at night (dLAN) impacts recovery from cardiac arrest and cardiopulmonary 
resuscitation (CA). (a) Ambient lighting in cardiac intensive care unit patient rooms. (b) dLAN 
increases mortality following CA in a rodent model. (c-g) dLAN exacerbates CA induced 
hippocampal cell death as indicated by Fluoro-JadeC staining. Representative Fluoro-JadeC 
stained sections from the CA1 of (c) LD-SH (d) dLAN-SH (e) LD-CA and (f) dLAN-CA mice.  
  
Figure 2. CA induced pro-inflammatory cytokine expression is elevated in the hippocampus and 
microglia of dLAN mice. Hippocampal (a) TNFα, (b) IL1β, and (c) IL6 gene expression are 
upregulated 24 hrs following CA and placement in dLAN. (d) TNF-α  expression is elevated as 
early as 6 hours post-CA and only 4 hours of dLAN. Microglial (e) TNFα, (f) IL1β, and (g) IL6 
gene expression are also altered 24 hrs following CA and placement in dLAN. (h) Serum 
corticosterone concentrations are unaffected by light at night.  
 Figure 3. Selective inhibition of specific pro-inflammatory cytokines blocks inflammation and 
neuronal cell death following CA and dLAN. (a) Percent survival following CA and treatment 
with different cytokine inhibitors (b) Neuronal damage in the hippocampus. (c) Proportional area 
of Iba1 staining in the CA1. Representative photomicrographs from the CA1 of mice treated with 
(d) LD-Veh (e) dLAN-Veh (f) dLAN-IL1ra (g) dLAN-IL6ab (h) dLAN-IFX. (i) Proportional 
area of Iba1 staining throughout the hippocampus.  
 Figure 4. Manipulation of lighting wavelength minimizes light at night induced damage 
following CA. (a) Percent survival following CA and placement in LD, dLAN, or rLAN. (b) 
Neuronal damage in the hippocampus. (c) Proportional area of Iba1 staining in the CA1. 
Representative photomicrographs of Flourojade staining from the CA1 of (d) LD (e) dLAN and 
(f) rLAN mice. Representative photomicrographs of Iba1 staining from the CA1 of (g) LD (h) 












Figure S1. (a) Mean arterial blood pressure (b) head temperature and (c) body temperature 









Figure S2. Corticosterone concentrations did not differ between LD and dLAN mice in the 24 h 
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